The expression of high-mobility group protein box 1 correlates with the progression of non-small cell lung cancer.

High-mobility group protein box 1 (HMGB1) released from dying tumor cells promotes tumor progression, on the other hand HMGB1 activates dendritic cells and triggers anti-neoplastic response of T-cells in chemotherapy and radiotherapy. HMGB1 expression is up-regulated in many kinds of tumors. To investigate HMGB1 expression in non-small cell lung cancer, 63 patients were enrolled and tumor tissues were collected with matched normal lung tissues. HMGB1 mRNA and protein levels were quantified with real-time PCR, Western blots and immunohistochemistry. The HMGB1 expression in tumor tissue was lower than in matched normal lung tissue at mRNA levels (Paired t-test, t<0.001) and the down-regulation in stage III-IV patients was also significantly greater than one in stage I-II (one-way ANOVA, p=0.005). At protein level, HMGB1 expression was also down-regulated. Low HMGB1 expression in non-small cell lung cancer may explain the poor therapeutical outcome during chemotherapy and radiotherapy.

[1]  Yan Ding,et al.  Increased expression of high mobility group box 1 (HMGB1) is associated with progression and poor prognosis in human nasopharyngeal carcinoma , 2008, The Journal of pathology.

[2]  P. Rovere-Querini,et al.  HMGB1: a two-headed signal regulating tumor progression and immunity. , 2008, Current opinion in immunology.

[3]  T. Billiar,et al.  HMGB1: Endogenous Danger Signaling , 2008, Molecular medicine.

[4]  J. Bullerdiek,et al.  Non-Hodgkin lymphoma expressing high levels of the danger-signalling protein HMGB1 , 2008, Leukemia & lymphoma.

[5]  M. Lotze,et al.  The grateful dead: damage‐associated molecular pattern molecules and reduction/oxidation regulate immunity , 2007, Immunological reviews.

[6]  Laurence Zitvogel,et al.  Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapy , 2007, Nature Medicine.

[7]  Herbert J. Zeh,et al.  Masquerader: High Mobility Group Box-1 and Cancer , 2007, Clinical Cancer Research.

[8]  L. Ulloa,et al.  High-mobility group box 1 (HMGB1) protein: friend and foe. , 2006, Cytokine & growth factor reviews.

[9]  R. Donato,et al.  The Amphoterin (HMGB1)/Receptor for Advanced Glycation End Products (RAGE) Pair Modulates Myoblast Proliferation, Apoptosis, Adhesiveness, Migration, and Invasiveness , 2006, Journal of Biological Chemistry.

[10]  M. Presta,et al.  Cutting Edge: Extracellular High Mobility Group Box-1 Protein Is a Proangiogenic Cytokine1 , 2006, The Journal of Immunology.

[11]  S. Joos,et al.  Increased expression of high mobility group box 1 (HMGB1) is associated with an elevated level of the antiapoptotic c-IAP2 protein in human colon carcinomas , 2005, Gut.

[12]  Kevin J. Tracey,et al.  High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal , 2005, Nature Reviews Immunology.

[13]  J. Enghild,et al.  Purification and Characterization of Mouse Soluble Receptor for Advanced Glycation End Products (sRAGE)* , 2004, Journal of Biological Chemistry.

[14]  R. Silber,et al.  Down-regulation of the receptor for advanced glycation end-products (RAGE) supports non-small cell lung carcinoma. , 2004, Carcinogenesis.

[15]  S. Müller,et al.  Regulated expression and subcellular localization of HMGB1, a chromatin protein with a cytokine function , 2004, Journal of internal medicine.

[16]  K. Tracey,et al.  Reversing established sepsis with antagonists of endogenous high-mobility group box 1 , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[17]  Stefan Joos,et al.  HMGB1 inhibits cell death in yeast and mammalian cells and is abundantly expressed in human breast carcinoma , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[18]  Hoguen Kim,et al.  Overexpression of high mobility group box 1 in gastrointestinal stromal tumors with KIT mutation. , 2003, Cancer research.

[19]  A. Bosserhoff,et al.  Upregulation of HMG1 Leads to Melanoma Inhibitory Activity Expression in Malignant Melanoma Cells and Contributes to Their Malignancy Phenotype , 2003, Molecular and Cellular Biology.

[20]  M. Bianchi,et al.  HMGB proteins and gene expression. , 2003, Current opinion in genetics & development.

[21]  K. Tracey,et al.  Ethyl pyruvate prevents lethality in mice with established lethal sepsis and systemic inflammation , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[22]  L. Borrmann,et al.  Variation of HMGB1 expression in breast cancer. , 2001, Anticancer research.

[23]  T. Kislinger,et al.  Blockade of RAGE–amphoterin signalling suppresses tumour growth and metastases , 2000, Nature.

[24]  K. Tracey,et al.  HMG-1 as a late mediator of endotoxin lethality in mice. , 1999, Science.

[25]  K. Sugimachi,et al.  Enhanced coexpression of thioredoxin and high mobility group protein 1 genes in human hepatocellular carcinoma and the possible association with decreased sensitivity to cisplatin. , 1996, Cancer research.

[26]  H. Rauvala,et al.  30-kDa heparin-binding protein of brain (amphoterin) involved in neurite outgrowth. Amino acid sequence and localization in the filopodia of the advancing plasma membrane. , 1991, The Journal of biological chemistry.

[27]  H. Fujii,et al.  Expression of high mobility group box chromosomal protein-1 (HMGB-1) in gastric cancer. , 2007, Anticancer research.

[28]  A. Bosserhoff,et al.  Transcription factors involved in development and progression of malignant melanoma. , 2004, Histology and histopathology.